CStone Pharmaceuticals

DB:PH4 Stock Report

Market Cap: €445.5m

CStone Pharmaceuticals Management

Management criteria checks 3/4

CStone Pharmaceuticals' CEO is Jason Yang, appointed in Aug 2022, has a tenure of 2.75 years. total yearly compensation is CN¥28.50M, comprised of 17.7% salary and 82.3% bonuses, including company stock and options. directly owns 1.27% of the company’s shares, worth €5.76M. The average tenure of the management team and the board of directors is 2.3 years and 6 years respectively.

Key information

Jason Yang

Chief executive officer

CN¥28.5m

Total compensation

CEO salary percentage17.72%
CEO tenure2.8yrs
CEO ownership1.3%
Management average tenure2.3yrs
Board average tenure6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jason Yang's remuneration changed compared to CStone Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024CN¥29mCN¥5m

-CN¥91m

Sep 30 2024n/an/a

-CN¥117m

Jun 30 2024n/an/a

-CN¥142m

Mar 31 2024n/an/a

-CN¥255m

Dec 31 2023CN¥58mCN¥5m

-CN¥367m

Sep 30 2023n/an/a

-CN¥559m

Jun 30 2023n/an/a

-CN¥750m

Mar 31 2023n/an/a

-CN¥827m

Dec 31 2022CN¥62mCN¥3m

-CN¥903m

Compensation vs Market: Jason's total compensation ($USD3.95M) is above average for companies of similar size in the German market ($USD917.60K).

Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.

CEO

Jason Yang (60 yo)

2.8yrs

Tenure

CN¥28,501,000

Compensation

Dr. Jianxin Yang, M.D., Ph D., also known as Jason, serves as President of R&D of CStone Pharmaceuticals since 2024 and was its Senior Vice President and Chief Medical Officer December 2016 until 2024. He...

Leadership Team

NamePositionTenureCompensationOwnership
Jianxin Yang
CEO, President of R&D and Executive Director2.8yrsCN¥28.50m1.27%
€ 5.7m
Weicong Ni
CFO & Joint Company Secretary2.3yrsno datano data
Ying Hua Zhang
Senior VP & Chief Operating Officer1.3yrsno datano data
Michael J. Choi
Chief Business & Strategy Officer4yrsno datano data
Yujuan La
Senior Vice President of Product Development4yrsno datano data
Qingmei Shi
Senior VP & Chief Medical Officer1.3yrsno datano data
Mei Yee Yung
Joint Company Secretaryless than a yearno datano data

2.3yrs

Average Tenure

48yo

Average Age

Experienced Management: PH4's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jianxin Yang
CEO, President of R&D and Executive Directorno dataCN¥28.50m1.27%
€ 5.7m
Yip Ho
Independent Non-Executive Directorless than a yearno datano data
Paul A. Bunn
Member of Scientific Advisory Board6.2yrsno datano data
Zhengguo Hu
Non-Executive Director3.8yrsCN¥459.00k0.068%
€ 302.3k
Hongbin Sun
Independent Non-Executive Director6.3yrsCN¥285.00kno data
Xianghong Lin
Non-Executive Director4.5yrsno datano data
Ting Yuk Wu
Independent Non-Executive Director6.3yrsCN¥712.00kno data
Kenneth Walton Hitchner
Non Executive Director3.4yrsCN¥354.00kno data
Weiping Zou
Member of Scientific Advisory Board5.9yrsno datano data
Paul Herbert Chew
Independent Non-Executive Director6.3yrsCN¥285.00kno data
Wei Li
Non-Executive Chairman9.4yrsCN¥459.00kno data

6.0yrs

Average Tenure

61yo

Average Age

Experienced Board: PH4's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 18:49
End of Day Share Price 2025/05/16 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CStone Pharmaceuticals is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
Ling WangJ.P. Morgan
Sean WuMorgan Stanley